Applying our synthetic lethality expertise for better cancer therapies
Dr. Dun Yang
Founder
Executive Chair
Chief Scientific Strategy Officer
OUR MISSION
To translate MYC-SL into biomarker-guided cancer therapies with meaningful clinical outcomes.
OUR VISION
To make MYC-driven cancers tractable through MYC-SL and structural-control therapeutics.
OUR STRENGTHS
MYC Biology · Synthetic Lethality · Architectural Control
GUNS-DF · MIPS · DrugGPT
Context-Optimized Assets · Scaffold-Diversified MYC-SL Compounds · Shared Biomarker Framework
PUBLICATIONS
Seeking a lasting immune attack to thwart cancer
MYC drop: Synthetic lethal drugs are targeting a common cancer culprit
Cancer has a vast range of genetic and epigenetic variations. A one-size-fits-all therapy is unfeasible, and personalized treatments are advancing.
